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ORIGINAL RESEARCH
Vitamin K Intake and Atherosclerotic 
Cardiovascular Disease in the Danish Diet 
Cancer and Health Study
Jamie W. Bellinge , MBBS; Frederik Dalgaard , MD, PhD; Kevin Murray , PhD; Emma Connolly, BNutrDiet (Hons); 
Lauren C. Blekkenhorst , PhD; Catherine P. Bondonno , PhD; Joshua R. Lewis , PhD; Marc Sim , PhD; 
Kevin D. Croft, PhD; Gunnar Gislason , MD, PhD; Christian Torp- Pedersen, MD, DMSc; Anne Tjønneland, MD, PhD; 
Kim Overvad, MD, PhD; Jonathan M. Hodgson , PhD; Carl Schultz , MBChB, PhD; Nicola P. Bondonno , PhD
BACKGROUND: Dietary vitamin K (K1 and K2) may reduce atherosclerotic cardiovascular disease (ASCVD) risk via several mech-
anisms. However, studies linking vitamin K intake with incident ASCVD are limited. We aimed to determine the relationship 
between dietary vitamin K intake and ASCVD hospitalizations.
METHODS AND RESULTS: In this prospective cohort study, participants from the Danish Diet, Cancer, and Health Study, with no 
prior ASCVD, completed a food- frequency questionnaire at baseline and were followed up for hospital admissions of ASCVD; 
ischemic heart disease, ischemic stroke, or peripheral artery disease. Intakes of vitamin K1 and vitamin K2 were estimated from 
the food- frequency questionnaire, and their relationship with ASCVD hospitalizations was determined using Cox proportional 
hazards models. Among 53 372 Danish citizens with a median (interquartile range) age of 56 (52– 60) years, 8726 individuals 
were hospitalized for any ASCVD during 21 (17– 22) years of follow- up. Compared with participants with the lowest vitamin 
K1 intakes, participants with the highest intakes had a 21% lower risk of an ASCVD- related hospitalization (hazard ratio, 0.79; 
95% CI: 0.74– 0.84), after multivariable adjustments for relevant demographic covariates. Likewise for vitamin K2, the risk of 
an ASCVD- related hospitalization for participants with the highest intakes was 14% lower than participants with the lowest 
vitamin K2 intake (hazard ratio, 0.86; 95% CI, 0.81– 0.91).
CONCLUSIONS: Risk of ASCVD was inversely associated with diets high in vitamin K1 or K2. The similar inverse associations 
with both vitamin K1 and K2, despite very different dietary sources, highlight the potential importance of vitamin K for ASCVD 
prevention.
Key Words: atherosclerotic cardiovascular disease ■ dietary vitamin K ■ phylloquinone ■ menaquinone ■ primary prevention ■ 
prospective cohort study
Atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of death worldwide de-spite the availability of risk- modifying therapies 
and lifestyle advice.1 The pathogenesis of ASCVD is 
multifactorial and is, in part, influenced by inflamma-
tion,2 impaired hemostasis,3 metabolic syndrome (in-
cluding dysglycemia, dyslipidemia, and obesity),4 and 
arterial calcification.5 These mechanisms are possible 
targets for dietary and pharmaceutical interventions 
aimed at reducing ASCVD risk.
Vitamin K occurs in 2 forms: Vitamin K1 (phylloqui-
none) is found in all photosynthetic plants, with green 
leafy vegetables being the primary dietary source, 
while vitamin K2 (menaquinones K4- K10) is primarily 
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bacterially derived and is found predominantly in fer-
mented foods, such as cheese.6 Both forms of vita-
min K have been proposed to influence cardiovascular 
health through many mechanisms,7 including the re-
duction of systemic inflammation,8 maintenance of he-
mostasis,9 and the inhibition of arterial calcification.10
Observational studies have demonstrated an in-
verse relationship between biomarkers of dietary vita-
min K intake and ASCVD risk,11– 14 and supplementing 
with vitamin K increases circulating concentrations of 
these biomarkers15,16 in a dose- dependent fashion.17 
These observations and others18 suggest a causal 
role of vitamin K in the prevention of ASCVD. However, 
observational studies linking dietary vitamin K1 intake 
with ASCVD risk in US men and women have been 
inconclusive,19,20 and observed inverse relationships 
are often attributed to the underlying cardioprotective 
dietary patterns associated with high vitamin K1 intake 
(eg, higher vegetable intake). In Dutch cohorts, high di-
etary vitamin K2 intake is associated with lower ASCVD 
risk21,22; this finding requires validation in other popu-
lations. Two recent meta- analyses have described an 
increased risk of all- cause mortality14 and coronary 
heart disease18 with vitamin K deficiency as defined 
by serum biomarkers or dietary intake, respectively. 
Further research is needed to validate these obser-
vations and better understand the effect of vitamin K 
deficiency on specific ASCVD subtypes.
We aimed to investigate whether dietary intakes of 
vitamin K1 and vitamin K2 were associated with total 
ASCVD hospitalizations and hospitalizations for sub-
types of ASCVD, namely, ischemic heart disease (IHD), 
ischemic stroke, and peripheral artery disease (PAD), 
in Danish individuals free of ASCVD at baseline.
METHODS
Because of the sensitive nature of the data collected 
for this study, requests to access the data set from 
qualified researchers trained in human subject confi-
dentiality may be sent to the Diet, Cancer, and Health 
Steering Committee at the Danish Cancer Society.
Study Population
Between 1993 and 1997, the Danish Diet, Cancer, and 
Health Study, an associated cohort of the European 
Prospective Investigation Into Nutrition and Cancer 
(EPIC),23 recruited 57 053 residents of the greater areas 
of Copenhagen and Aarhus, between the ages of 50 
and 65  years. Of these, 56  468 completed a food- 
frequency questionnaire (FFQ) and had no prevalent 
cancer at the time of recruitment. Using the Danish civil 
registration system, which assigns a unique and per-
manent number for all Danish residents, participants 
were able to be linked to the following registries on an 
individual level: (1) the Civil Registration System,24 con-
taining data on age, sex, emigration, and vital status; (2) 
the Integrated Database for Labour Market Research,25 
containing information on annual income since 1980; 
(3) the Danish National Prescription Registry, contain-
ing information on all filled prescriptions since 199426; 
and (4) the Danish National Patient Register (DNPR)27 
containing information on date of hospital admissions 
since 1978, with 1 primary diagnosis and ≥1 secondary 
diagnoses defined by the International Classification of 
Diseases (ICD) using the Eighth Revision (ICD- 8) until 
1993 and the Tenth Revision (ICD- 10) from 1994. In the 
DNPR, procedures and surgeries have been recorded 
since 1996 using Nordic Classification of Surgical 
Procedures codes.
All participants provided informed consent as part 
of the Danish Diet, Cancer, and Health Study to search 
information from medical registers.23 In the Danish 
Diet, Cancer, and Health Study, the procedures fol-
lowed were in accordance with the ethical standards of 
the responsible institutional or regional committee on 
human experimentation. In Denmark, register studies 
do not require approval from the ethics committees. 
CLINICAL PERSPECTIVE
What Is New?
• Dietary vitamin K1 and vitamin K2 intake is non-
linearly inversely associated with risk of athero-
sclerotic cardiovascular disease events.
• This relationship is true for all subtypes of ath-
erosclerotic cardiovascular disease, ischemic 
heart disease, ischemic stroke, and peripheral 
artery disease.
What Are the Clinical Implications?
• Dietary vitamin K intake may be considered in 
evaluating risk of atherosclerotic cardiovascular 
disease.
• Sufficient vitamin K intake may be protective of 
atherosclerotic cardiovascular disease events.
• Further research is needed to determine 
at- risk individuals who may benefit from in-
creased dietary vitamin K intake or vitamin K 
supplementation.
Nonstandard Abbreviations and Acronyms
DNPR Danish National Patient Register
FFQ food- frequency questionnaire
IHD ischemic heart disease
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This study was approved by the Danish Data Protection 
Agency (Reference no. 2012- 58- 0004 I- Suite nr: 6357, 
VD- 2018- 117).
In the present study, the main exclusion criteria in-
cluded prevalent ASCVD (n=2484), use of a vitamin K 
antagonist (VKA; n=220), missing or implausible values 
for covariates (n=196), or implausible energy intakes 
(n=196) (Figure  1). Prevalent ASCVD was defined by 
self- reported myocardial infarction (n=223), prior di-
agnosis of IHD (ICD- 8: 410– 412, 414; ICD- 10: I21– I25; 
n=1303), self- reported ischemic stroke (n=422), prior 
diagnosis of ischemic stroke (ICD- 8: 433– 434; ICD- 10: 
I63; n=199), or prior diagnosis of PAD (ICD- 8: 440– 
444; ICD- 10: I70– I74; n=337) at baseline (1993– 1997). 
Implausible energy intakes were defined as <2092 kJ/d 
(<500  kcal/d) and >20  920  kJ/d (>5000  kcal/d) and 
VKAs are defined using Anatomical Therapeutic 
Chemical code B01AA.
Exposures
Exposures were intakes of vitamin K1 and vitamin K2 
(menaquinones K- 4 to K- 10). These were estimated 
from dietary data, collected using a validated 192- item 
self- administered, semiquantitative FFQ mailed out to 
participants before their visit to 1 of the 2 study cent-
ers.28,29 The FFQ was validated against 2 times 7 days 
of weighed diet records29 where correlations between 
mean calorie- adjusted intakes from the weighed diet 
records and the FFQ were calculated for macro- and 
micronutrients. On average, 70% of the subjects were 
classified in the same (±1) quintile for macro- and mi-
cronutrient intakes when comparing the 2 different 
methods of capturing diet. On the FFQ, participants 
were asked to indicate their usual frequency of intake 
for different food and beverage items over the previous 
12 months, using a 12- category frequency scale that 
ranged from never to ≥8 times per day.22 Estimates of 
the vitamin K1 content of each food and beverage in 
the FFQ were derived from the Frida Food Data data-
base30 and, where a vitamin K1 value was not available, 
the US Department of Agriculture31 nutrient database. 
Estimates of the vitamin K2 content of each food and 
beverage in the FFQ were derived from Schurgers et 
al (menaquinones K- 4 to K- 932), and Manoury et al 
(menaquinone K- 1033), with total vitamin K2 intake cal-
culated by summing each of the individual menaqui-
nones, as done previously.34 Total dietary vitamin K 
intake was estimated by multiplying the food/bever-
age item consumed (g/d) by the mean vitamin K value 
(μg/g). A value of 0  µg/g was given to all foods and 
beverages where no value was available (vitamin K1, 
n=44; menaquinones K- 4 to K- 9, n=78; menaquinone 
K- 10, n=160). Information on the exact values used and 
assumptions made will be provided upon reasonable 
request to the corresponding author.
Study Outcomes
The primary outcome was a combined end point of 
first- time ASCVD hospitalization, defined as hospi-
talization for IHD, ischemic stroke, or PAD. Secondary 
Figure 1. Consolidated Standards of Reporting Trials flow diagram.
ASCVD indicates atherosclerotic cardiovascular disease; FFQ, food- frequency questionnaire; and 
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outcomes were a first- time hospitalization for IHD, is-
chemic stroke hospitalizations, and PAD hospitaliza-
tions, individually. Reasons for hospitalization were 
determined using ICD- 10 codes for primary or sec-
ondary diagnoses (IHD, ICD- 10: I21– I25; ischemic 
stroke, ICD- 10: I63; PAD, ICD- 10: I70– I74]. These ICD 
codes have previously been validated to varying de-
grees in the DNPR35– 38 and have positive predictive 
values of ≈92% to 97% for IHD,34 ≈81% to 85% for 
ischemic stroke,35 and ≈81% for PAD.36 Percutaneous 
coronary interventions (PCI; Nordic Classification of 
Surgical Procedures codes KFNG00, FNG02, FNG05, 
FNG10, FNG12, and FNG96) and coronary artery by-
pass grafting (CABG; Nordic Classification of Surgical 
Procedures codes KFNA, KFNB, KFNC, KFND, KFNE, 
and KFNH20) were investigated using a landmark 
analysis; as the procedure codes of coronary interven-
tions were not recorded before 1996, PCI and CABG 
were not included within the primary outcome. In this 
landmark analysis, participants who died, had an 
ASCVD event, or were prescribed a VKA before this 
date (January 1, 1996) were excluded (n=177 excluded; 
n=53 195 remaining in analysis). Diagnoses of unstable 
angina or transient ischemic attack were not included 
as outcomes as they lack validity in the DNPR.
Validated Case Analysis
To strengthen our findings, we reexamined asso-
ciations using only medically reviewed and validated 
cases of ASCVD to verify registry- based outcomes. 
Patients with an ICD- 10 discharge code for ischemic 
stroke or PAD up until 2009, or myocardial infarction 
up until 2013, registered as a primary or secondary 
diagnosis, were considered as possible cases to be 
reviewed (Table S1). Methods of case validation have 
been published previously.35– 39 Due to a prior diagno-
sis of validated ASCVD, a further 6 participants were 
excluded in this analysis (n=53 366).
Covariates
Information on sex, age, education, smoking habits, 
alcohol consumption, and daily activity was obtained 
from self- administered questionnaires completed by 
participants upon enrollment in the study. Dietary data 
were obtained from the semiquantitative FFQ described 
above. Annual income, averaged over the 5 years im-
mediately preceding study enrollment, was used as a 
proxy for socioeconomic status and was defined as 
household income after taxation and interest, for the 
value of the Danish currency in 2015. ICD- 8 and ICD- 10 
codes were used for diagnosis of chronic kidney dis-
ease (ICD- 8: 580– 584; ICD- 10: N02– N08, N11– N12, 
N14, N18– N19, N26, N158– N160, N162– N164, N168, 
Q61, E102, E112, E132, E142, I120, M321B), chronic ob-
structive pulmonary disease (ICD- 8: 491– 493; ICD- 10: 
J42– J44), heart failure (ICD- 8: 4270– 4271; ICD- 10: I42, 
I50, I110, J81), atrial fibrillation (ICD- 8: 42793– 42794; 
ICD- 10: I48), and cancers (ICD- 8: 140– 209; ICD- 10: 
C00– C99). For diabetes mellitus, only self- reported 
data were used because of the low validity of ICD codes 
in DNPR.39 Information regarding use of antihyperten-
sive medication and statins at study enrollment was 
obtained from a combination of self- reported use and 
Anatomical Therapeutic Chemical codes in the Danish 
National Prescription Registry: prescriptions of statins 
(Anatomical Therapeutic Chemical code C10AA), or 
antihypertensive medication (Anatomical Therapeutic 
Chemical codes described in Table S2), claimed within 
180 days before enrollment in the study, were identi-
fied from 1994. Presence of hypertension at baseline 
was defined as either self- reported hypertension or a 
claimed prescription of ≥2 antihypertensive medica-
tions within 180 days before study enrollment, which 
has a positive predictive value of 80.0% and a speci-
ficity of 94.7% to predict hypertension.40 Presence of 
hypercholesterolemia was defined using self- reported 
data, and anthropometric measurements were taken 
and total blood cholesterol was measured at the study 
centers.
Statistical Analysis
Participants’ time to event was based on a maximum 
of 23  years of follow- up from the date of enrollment 
until the date of death, emigration, ASCVD hospitaliza-
tion (first hospitalization for the combined end point), or 
end of follow- up (August 2017), whichever came first. 
Cox proportional hazards models with restricted cubic 
splines were used to investigate nonlinear relation-
ships between vitamin K intakes and all time- to- event 
outcomes. All hazard ratios (HRs) and 95% CIs were 
obtained from the model with the exposure fitted as a 
continuous variable through a restricted cubic spline 
(4 knots); HR estimates are reported for the median 
intake in each quintile, with the first quintile median as 
the reference point, and are also graphed over a fine 
grid of x values. For visual simplicity, the graphs of HRs 
derived from the fitting of cubic splines had x- axis val-
ues restricted to intakes within 3 SDs of the mean. Cox 
proportional hazards assumptions were tested using 
log- log plots of the survival function versus time and 
assessed for parallel appearance, with no violation 
found. We tested for nonlinearity using a chi- squared 
test to compare nested models. The relationship be-
tween ASCVD and all continuous covariates, except 
vitamin K, was assessed for linearity, and in the case of 
violation, covariates were transformed to be categori-
cal. As our aim was to obtain relative estimates for risk 
factors, all deaths were censored rather than treated 
as a competing risk.41 Five models of adjustment were 
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sex; model 1b (multivariable- adjusted) included age, 
sex, body mass index, smoking status, physical ac-
tivity, alcohol intake, socioeconomic status (income), 
and education; model 2 (covariates that are both po-
tential confounders and potential intermediates on 
the causal pathway) included all covariates in model 
1b plus hypertension, hypercholesterolemia, and 
prevalent disease (diabetes mellitus, chronic obstruc-
tive pulmonary disease, chronic kidney disease, and 
cancer; entered into the model separately); model 
3a (multivariable- adjusted including potential dietary 
confounders) included all covariates in model 1b plus 
energy and intakes of fish, red meat, processed food, 
polyunsaturated fatty acids, monounsaturated fatty 
acids, and saturated fatty acids; model 3b adjusted for 
all covariates in model 3a plus vitamin K1 or vitamin K2, 
as appropriate. Covariates were chosen a priori using 
knowledge of potential confounders of vitamin K intake 
and ASCVD. We tested for interactions between vita-
min K intake (quintiles) and sex using chi- squared tests 
to compare nested models. To understand whether 
an association between vitamin K1 and ASCVD is in-
dependent of total vegetable intake, we stratified our 
analysis by tertiles of total vegetable intake. To assess 
the likelihood of residual confounding, we used a fal-
sification end point that we considered likely to be af-
fected by diet but unlikely to be causally affected by 
vitamin K intake: colorectal cancer (ICD- 10: C18– C21; 
ICD- 8: 153– 154). We performed 2 sensitivity analyses. 
In the first sensitivity analysis, participants were cen-
sored if prescribed a VKA during follow- up, as these 
may affect the potential relationship between vitamin K 
intake and ASCVD, and such prescriptions may have 
been accompanied by recommendations for dietary 
change. In a second sensitivity analysis, with PCI and 
CABG as a combined outcome, a landmark analysis 
was performed with the landmark date of January 1, 
1996. Analyses were undertaken using STATA/IC 14.2 
(StataCorp LLC) and R statistics (R Core Team, 2019).
RESULTS
This population of 53 372 Danish citizens, with a me-
dian (interquartile range) age of 56 (52– 60) years at 
entry, had a median (interquartile range) follow- up of 
21 (17– 22) years. During 944 247 person- years of fol-
low- up, 8726 individuals were hospitalized for ASCVD, 
5290 for IHD, 2913 for ischemic stroke, and 1856 for 
PAD. Furthermore, 9476 participants died without a 
prior hospitalization for ASCVD and <0.3% of partici-
pants were lost to follow- up.
Baseline Characteristics
At baseline, the median (interquartile range) intake of 
vitamin K1 was 113.8 µg/d (80.7– 151.2) and vitamin K2 
was 43.7  µg/day (31.1– 61.5); intakes of the 2 forms 
of vitamin K were weakly correlated (Spearman’s 
rho=0.25). Compared with participants in the lowest 
quintile of vitamin K1 intake, those in the highest quin-
tile were more likely to be more physically active, have 
never smoked, have a higher degree of education, have 
a higher income, have a higher total energy intake, and 
have an overall healthier underlying dietary pattern, 
eating more fish, fiber, vegetables, and fruit (Table 1). 
For vitamin K2 intake, compared with participants in 
the lowest- intake quintile, those in the highest- intake 
quintile were more likely to be men, be more physically 
active, smoke, have a higher total energy intake, and 
have an overall unhealthier underlying dietary pattern, 
eating more red meat, processed meat, and saturated 
fat (Table  1). The main dietary sources of vitamin K1 
were margarine, lettuce, broccoli, whole- meal bread, 
and spinach, while eggs, butter, and hard cheeses 
were the main dietary sources of vitamin K2 (Table S3).
Associations Between Vitamin K1 Intake 
and ASCVD Hospitalizations
The association between vitamin K1 intake and inci-
dent ASCVD was nonlinear (P for nonlinearity <0.001); 
the steepness of the inverse association started to de-
crease at ≈100  µg/d (Figure  2). Compared with par-
ticipants in quintile 1, participants in quintile 5 had a 
21% lower risk of an ASCVD- related hospitalization 
(HR, 0.79; 95% CI, 0.74– 0.84) after multivariable ad-
justments (Model 1b; Table 2). For ASCVD subtypes, 
participants in quintile 5 had a 14% lower risk of a hos-
pitalization for IHD (HR, 0.86; 95% CI, 0.80– 0.93), a 
17% lower risk of hospitalization for an ischemic stroke 
(HR, 0.83; 95% CI, 0.75– 0.91), and a 34% lower risk 
of a PAD- related hospitalization (HR, 0.66; 95% CI, 
0.58– 0.75), after multivariable adjustments (model 1b) 
and compared with participants in quintile 1. A clear 
association between vitamin K1 intake and ASCVD re-
mained after adjusting for potential dietary confound-
ers (model 3a), including vitamin K2 intake (model 3b). 
The association between vitamin K1 and ASCVD was 
not modified by sex (P for interaction=0.533).
Associations Between Vitamin K2 Intake 
and ASCVD Hospitalizations
The association between total vitamin K2 intake and 
incident ASCVD hospitalizations was also nonlinear (P 
for nonlinearity <0.001; Figure 3). After multivariable ad-
justments (model 1b) and compared with participants 
in quintile 1, participants in quintile 5 had a 14% lower 
risk of ASCVD (HR, 0.86; 95% CI, 0.81– 0.91) and, more 
specifically, a 14% lower risk of a hospitalization for IHD 
(HR, 0.86; 95% CI, 0.80– 0.92), a 13% lower risk of a 
stroke hospitalization (HR, 0.87; 95% CI, 0.79– 0.95), 
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Table 1. Baseline Characteristics of Study Population
Total Population  
N=53 372
Total Vitamin K1 Intake Quintiles Total Vitamin K2 Intake Quintiles
Quintile 1  
n=10 675
Quintile 5  
n=10 675
Quintile 1  
n=10 675
Quintile 5  
n=10 675
Total vitamin K1 intake, µg/d 113.8 [80.7– 151.2] 57 [4– 73] 192 [162– 800] … …
Total vitamin K2 intake, µg/d 43.7 [31.1– 61.5] … … 23 [0– 29] 77 [65– 296]
Sex, male 24 826 (46.5) 4845 (45.4) 5022 (47.0) 4033 (37.8) 5725 (53.6)
Age, y 56 [52– 60] 56 [52– 60] 55 [52– 60] 56 [52– 60] 55 [52– 60]
BMI, kg/m2 26 [23– 28] 26 [24– 29] 25 [23– 27] 25 [23– 28] 26 [23– 28]
MET score 56 [37– 84] 50 [32– 77] 64 [42– 92] 52 [34– 78] 61 [40– 91]
Smoking status
Never 19 195 (36.0) 2995 (28.1) 4242 (39.7) 4088 (38.3) 3624 (33.9)
Former 15 140 (28.4) 2471 (23.1) 3484 (32.6) 2835 (26.6) 3173 (29.7)
Current 19 037 (35.7) 5209 (48.8) 2949 (27.6) 3752 (35.1) 3878 (36.3)
Education
≤7 y 17 225 (32.3) 4709 (44.1) 2294 (21.5) 3512 (32.9) 3516 (32.9)
8– 10 y 24 767 (46.4) 4779 (44.8) 4754 (44.5) 5117 (47.9) 4651 (43.6)
≥11 y 11 357 (21.3) 1182 (11.1) 3622 (33.9) 2040 (19.1) 2503 (23.4)
Mean household income
≤394 700 DKK/y 13 010 (24.4) 3468 (32.5) 2305 (21.6) 2816 (26.4) 2807 (26.3)
394 701– 570 930 DKK/y 13 255 (24.8) 3016 (28.3) 2272 (21.3) 2602 (24.4) 2722 (25.5)
570 931– 758 297 DKK/y 13 441 (25.2) 2500 (23.4) 2408 (22.6) 2525 (23.7) 2685 (25.2)
>758 297 DKK/y 13 666 (25.6) 1691 (15.8) 3690 (34.6) 2732 (25.6) 2461 (23.1)
Hypertensive 8288 (15.5) 1741 (16.3) 1529 (14.3) 1793 (16.8) 1543 (14.5)
Hypercholesterolemic 3373 (6.3) 681 (6.4) 618 (5.8) 943 (8.8) 507 (4.7)
Comorbidities
Diabetes mellitus 992 (1.9) 158 (1.5) 309 (2.9) 159 (1.5) 319 (3.0)
Heart failure 78 (0.1) 23 (0.2) 12 (0.1) 18 (0.2) 15 (0.1)
Atrial fibrillation 165 (0.3) 43 (0.4) 28 (0.3) 36 (0.3) 31 (0.3)
COPD 744 (1.4) 208 (1.9) 135 (1.3) 150 (1.4) 155 (1.5)
CKD 176 (0.3) 30 (0.3) 26 (0.2) 32 (0.3) 39 (0.4)
Cancer 224 (0.4) 51 (0.5) 35 (0.3) 49 (0.5) 47 (0.4)
Medication use
Insulin treated 330 (0.6) 43 (0.4) 129 (1.2) 44 (0.4) 123 (1.2)
Antihypertensive 6079 (11.4) 1290 (12.1) 1107 (10.4) 1295 (12.1) 1105 (10.4)
Statin 621 (1.2) 126 (1.2) 122 (1.1) 202 (1.9) 76 (0.7)
HRT, % of women
Never 15 524 (54.4) 3144 (53.9) 3038 (53.7) 3612 (54.4) 2740 (55.4)
Current 8594 (30.2) 1702 (29.2) 1747 (30.9) 1992 (30.0) 1466 (29.6)
Former 4397 (15.4) 973 (16.7) 865 (15.3) 1030 (15.5) 739 (14.9)
NSAID 17 045 (32.1) 3377 (31.9) 3404 (32.0) 3386 (31.9) 3478 (32.8)
Aspirin 6468 (12.1) 1378 (12.9) 1242 (11.6) 1274 (11.9) 1402 (13.1)
Dietary characteristics










Total fish intake, g/d 38 [25– 55] 28 [18– 41] 49 [33– 68] 31 [20– 44] 44 [29– 64]
Red meat intake, g/d 78 [56– 107] 69 [51– 93] 83 [58– 117] 64 [46– 87] 91 [66– 124]
Processed meat intake, g/d 24 [14– 40] 24 [14– 40] 23 [12– 39] 18 [10– 29] 31 [18– 50]
Dietary fiber intake, g/d 20 [16– 25] 14 [12– 17] 27 [23– 32] 17 [13– 22] 24 [20– 29]
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HR, 0.88; 95% CI, 0.78– 0.99). An association between 
vitamin K2 intake and ASCVD remained after adjusting 
for potential dietary confounders (model 3a), including 
vitamin K1 intake (model 3b). The association between 
vitamin K2 and ASCVD was not modified by sex (P for 
interaction=0.593).
Stratified Analyses
To try to understand whether vitamin K1 intake is only a 
marker of higher vegetable intake (Spearman’s rho for 
correlation between vitamin K1 intake and total vegeta-
ble intake=0.82), we stratified our analysis by tertiles of 
total vegetable intake. Compared with those with a low 
vitamin K1 intake 1 (quintile 1), those with a high vitamin 
K1 intake had a lower risk of ASCVD hospitalizations 
across each tertile of total vegetable intake; lowest 
tertile HR quintile 5 vs quintile 1, 0.74; 95% CI, 0.55– 
0.99)], middle tertile (HR quintile 5 vs quintile 1, 0.61 
(95% CI, 0.50– 0.75)] and highest tertile (HR quintile 5 
vs quintile 1, 0.73; 95% CI, 0.58– 0.93) (Table S4).
Validated Case Analysis
Using only validated cases, 3463 participants were 
hospitalized for any ASCVD, 2488 were hospitalized for 
an myocardial infarction, 920 for an ischemic stroke, 
and 816 for PAD. For vitamin K1 intake, compared with 
Total Population  
N=53 372
Total Vitamin K1 Intake Quintiles Total Vitamin K2 Intake Quintiles
Quintile 1  
n=10 675
Quintile 5  
n=10 675
Quintile 1  
n=10 675
Quintile 5  
n=10 675
Polyunsaturated FA, g/d 13 [10– 17] 10 [8– 12] 17 [13– 22] 10 [8– 13] 16 [13– 21]
Monounsaturated FA, g/d 27 [21– 35] 23 [18– 30] 31 [24– 39] 20 [16– 25] 35 [28– 43]
Fruit intake, g/d 172 [95– 282] 104 [47– 183] 251 [156– 386] 149 [76– 257] 193 [114– 319]
Vegetable intake, g/d 162 [105– 231] 73 [52– 100] 287 [231– 354] 133 [81– 199] 191 [129– 266]
Alcohol intake, g/d 13 [6– 31] 12 [4– 32] 13 [6– 30] 11 [4– 27] 13 [6– 31]
Data expressed as median [IQR] or n (%), unless otherwise stated.
BMI indicates body mass index; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DKK, Danish Krone; FA, fatty acid; HRT, 
hormone replacement therapy; MET, metabolic equivalent; and NSAID, nonsteroidal anti- inflammatory drug.
Table 1. Continued
Figure 2. Hazard ratios from Cox proportional hazards model with restricted cubic 
spline curves describing the association between vitamin K1 intake (µg/d) and both total 
atherosclerotic cardiovascular disease (ASCVD) hospitalizations and subtypes of ASCVD 
hospitalizations (ischemic heart disease, peripheral artery disease, and ischemic stroke).
Hazard ratios are based on models adjusted for age, sex, body mass index, smoking status, 
social economic status (income), physical activity, alcohol intake, and education (model 1b), and 
are comparing the specific level of vitamin K1 intake (horizontal axis) to the median intake for 
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participants in quintile 1 and after multivariable adjust-
ments (model 1b), participants in quintile 5 had a 22% 
lower risk of stroke (HR, 0.78; 95% CI, 0.65– 0.94), a 
nonsignificant 9% lower risk of an myocardial infarction 
(HR, 0.91; 95% CI, 0.81– 1.02), and a 34% lower risk of 
having PAD (HR, 0.66; 95% CI, 0.54– 0.80) (Figure S1). 
For vitamin K2 intake, compared with participants in 
quintile 1 and after multivariable adjustments (model 
1b), participants in quintile 5 had a 16% lower risk of 
an myocardial infarction (HR, 0.84; 95% CI, 0.76– 0.93), 
and a 16% lower risk of having PAD (HR, 0.84; 95% CI, 
0.70– 1.01). Vitamin K2 intake was not significantly as-
sociated with validated stroke cases (Figure S1).
Sensitivity Analyses
Censoring participants upon the prescription of a VKA 
did not change the association between vitamin K1 or 
vitamin K2 intakes and ASCVD (Figures S2 and S3). For 
vitamin K1 intake, compared with participants in quin-
tile 1 and after multivariable adjustments (model 1b), 
participants in quintile 5 had a 12% lower risk of having 
a PCI or CABG procedure during follow- up (HR, 0.88; 
95% CI, 0.80, 0.96) (Figure S4). For vitamin K2 intake, 
participants in quintile 5 had a 14% lower risk of having 
a PCI or CABG procedure during follow- up (HR, 0.86; 
95% CI, 0.78– 0.94).
Falsification End Point Analysis
In total, 1716 participants were hospitalised for colo-
rectal cancer over the study period. There was no sig-
nificant association between intakes of either vitamin 
K1 or vitamin K2 and our falsification end point, colo-
rectal cancer (Table S5).
DISCUSSION
In this large prospective cohort study of Danish indi-
viduals, we observed that both vitamin K1 and vitamin 
K2 intakes were independently, inversely, and nonlin-
early associated with ASCVD hospitalizations. The as-
sociation between both forms of vitamin K and ASCVD 
hospitalizations was present for all ASCVD subtypes.
Table 2. Hazard Ratios of Cardiovascular Disease Hospitalizations by Quintiles of Vitamin K Intake
Vitamin K Intake Quintiles
Quintile 1  
n=10 675
Quintile 2  
n=10 674
Quintile 3  
n=10 675
Quintile 4  
n=10 674
Quintile 5  
n=10 674
Vitamin K1
No. events 2142 1863 1689 1526 1506











Model 1a ref. 0.81 (0.78– 0.84) 0.73 (0.69– 0.76) 0.68 (0.65– 0.72) 0.63 (0.60– 0.67)
Model 1b ref. 0.88 (0.85– 0.92) 0.84 (0.80– 0.88) 0.82 (0.78– 0.87) 0.79 (0.74– 0.84)
Model 2 ref. 0.88 (0.85– 0.92) 0.84 (0.80– 0.88) 0.82 (0.77– 0.86) 0.78 (0.73– 0.82)
Model 3a ref. 0.89 (0.85– 0.93) 0.85 (0.81– 0.90) 0.85 (0.79– 0.91) 0.83 (0.76– 0.91)
Model 3b ref. 0.89 (0.85– 0.93) 0.86 (0.81– 0.90) 0.85 (0.79– 0.91) 0.83 (0.76– 0.91)
Vitamin K2
No. events 1774 1746 1831 1616 1759











Model 1a ref. 0.98 (0.94– 1.02) 0.93 (0.88– 0.97) 0.86 (0.82– 0.91) 0.87 (0.83– 0.92)
Model 1b ref. 0.98 (0.94– 1.02) 0.93 (0.89– 0.98) 0.86 (0.82– 0.91) 0.86 (0.81– 0.91)
Model 2 ref. 0.99 (0.96– 1.03) 0.95 (0.90– 0.99) 0.88 (0.83– 0.93) 0.87 (0.82– 0.92)
Model 3a ref. 0.98 (0.94– 1.02) 0.94 (0.89– 0.99) 0.89 (0.84– 0.95) 0.90 (0.84– 0.97)
Model 3b ref. 0.98 (0.95– 1.03) 0.95 (0.90– 1.00) 0.89 (0.84– 0.95) 0.91 (0.84– 0.97)
Hazard ratios (95% CI) for atherosclerotic cardiovascular disease hospitalizations during 23 years of follow- up, obtained from restricted cubic splines based 
on Cox proportional hazards models, comparing the median intake in quintiles 2– 5, to the median intake in quintile 1. Model 1a adjusted for age and sex; model 
1b adjusted for age, sex, body mass index, smoking status, physical activity, alcohol intake, social economic status (income), and education; model 2 adjusted 
for all covariates in model 1b plus hypertension, hypercholesterolemia, and prevalent disease (diabetes mellitus, chronic obstructive pulmonary disease, chronic 
kidney disease, and cancer; entered into the model separately); Model 3a adjusted for all covariates in model 1b plus energy and intakes of fish, red meat, 
processed food, polyunsaturated fatty acids, monounsaturated fatty acids, and saturated fatty acids; Model 3b adjusted for all covariates in model 3a plus 
vitamin K1 or vitamin K2, as appropriate.
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In the present study, participants in the highest vi-
tamin K1 intake quintile (median 192 μg/d) had a 14%, 
17%, and 34% lower risk of an IHD- , stroke- , and PAD- 
related hospitalization, respectively, compared with 
those in the lowest- intake quintile (median, 57 μg/d). 
Similar findings have been observed in 2 large obser-
vational cohort studies investigating the association 
between dietary vitamin K1 intake and ASCVD events. 
Two studies, the Nurses’ Health study (72 874 female 
nurses; 1679 coronary heart disease events)19 and the 
Health Professionals’ Follow- up study (40  087 male 
health care professionals; 1857 coronary heart disease 
events),20 report a 21% lower risk and a 16% lower risk 
of coronary heart disease events, respectively. In con-
trast, prior studies have not observed a relationship 
between vitamin K1 intake and stroke
19,20,42 or PAD.43 
Interestingly, the median vitamin K1 intake in cohorts 
from other studies19– 22,42– 44 exceeds the median intake 
of vitamin K1 in the current study. The low vitamin K1 
intake in the current study, most apparent in the lowest 
quintile, serves as an important comparator providing 
adequate power to detect the cardioprotective poten-
tial of high vitamin K1 intake, while also identifying the 
detrimental impact of low vitamin K1 intake on ASCVD 
risk, which is most apparent below ≈50 μg/d.
Vitamin K2 intake was inversely associated with a 
14% lower risk of ASCVD hospitalizations, and this 
association was present for all ASCVD subtypes. In 
the Prospect- EPIC cohort (16 057 women; 480 cor-
onary heart disease events), a 10 μg/day higher vi-
tamin K2 intake was associated with a 9% lower risk 
of coronary heart disease.22 In the Rotterdam Study 
(4807 men and women; 233 coronary heart disease 
events), individuals in the highest tertile of vitamin 
K2 intake had a 41% lower risk of incident coronary 
heart disease compared with those in the lowest 
tertile.21 Another study of 35 476 Dutch individuals, 
with a comparatively lower baseline vitamin K2 intake 
(mean 30.7 μg/d), observed no relationship between 
vitamin K2 intake and risk of stroke.
42 However, this 
cohort had a young mean age of 49 ± 12 years with 
high prevalence of hypertension (36.8%), accruing 
only 324 cases of ischemic stroke during a mean 
follow- up of 12  years. Vissers et al43 reported, in a 
large prospective cohort study (36 629 participants; 
489 events), a dose- responsive reduction in PAD in-
cidence for higher vitamin K2 intakes (HR per 10 μg/d 
higher intake, 0.92; 95% CI, 0.85– 0.99), supporting 
the inverse association with vitamin K2 observed in 
our study. In the present study, the median vitamin K2 
intake is mostly higher than the median vitamin K2 in-
takes in other studies that have identified a beneficial 
association between vitamin K2 intake and ASCVD 
risk.21,22,43,44 However, the relatively higher vitamin 
Figure 3. Hazard ratios from Cox proportional hazards model with restricted cubic 
spline curves describing the association between vitamin K2 intake (µg/d) and both total 
atherosclerotic cardiovascular disease (ASCVD) hospitalizations and subtypes of ASCVD 
hospitalizations (ischemic heart disease, peripheral artery disease, and ischemic stroke).
Hazard ratios are based on models adjusted for age, sex, body mass index, smoking status, 
social economic status (income), physical activity, alcohol intake, and education (model 1b), and 
are comparing the specific level of vitamin K2 intake (horizontal axis) to the median intake for 
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K2 intake in our cohort permitted the discovery of a 
nonlinear, and in fact more “U- shaped” association 
between vitamin K2 intake and ASCVD risk, which, to 
the best of our knowledge, has not previously been 
described. This may reflect a competing increase in 
ASCVD risk associated with overconsumption of vi-
tamin K2- rich foods (ie, cheese, eggs, butter).
Corroborating the findings of the current study, a re-
cent meta- analysis of 3 separate cohorts totaling 3891 
participants described an 18% higher risk of the com-
bined end point of cardiovascular disease (858 events) 
or all- cause mortality (1209 events) in those individuals 
with low circulating vitamin K1 (≤0.5 nmol/L) compared 
with those with high circulating vitamin K1 (>1.0 nmol/L).
14 
This difference was driven mostly by all- cause mortal-
ity. Another meta- analysis of 1190 participants from 3 
studies quantified functional vitamin K deficiency using 
plasma dephosphorylated- uncarboxylated Matrix Gla 
protein. The authors describe a 57% higher risk of car-
diovascular disease events (220 events) in the highest 
tertile (reflecting relative functional vitamin K deficiency), 
compared with the lowest tertile of dephosphorylated- 
uncarboxylated Matrix Gla protein.18 In the same study, 
the authors observed an 8% lower risk of total coronary 
heart disease events for vitamin K1 (4249 events),
19– 22 and 
a 30% lower risk for vitamin K2 (713 events),
21,22 compar-
ing the highest and lowest tertiles of dietary intake. No 
association was observed between vitamin K1 and either 
nonfatal myocardial infarction or stroke, or between vi-
tamin K2 and fatal coronary heart disease. The findings 
of the present study support the association observed 
for coronary heart disease and additionally provide novel 
information on the protective associations of both vita-
min K1 and vitamin K2 with stroke, PAD, and indeed, total 
ASCVD events.
There are several mechanisms by which vitamin K 
may lower the risk of ASCVD events. Systemic inflam-
mation is an important component of ASCVD initiation 
and propagation, and inhibiting the systemic inflamma-
tory process reduces cardiovascular disease events.2 
Serum vitamin K1 levels have been inversely related 
to serum inflammatory markers in large prospective 
cohort studies.8 Consequently, suppressing systemic 
inflammation may explain a net reduction in ASCVD 
events. Additionally, vitamin K may assist in regulating 
insulin resistance45,46 and hemostasis,9 both important 
in the pathogenesis of ASCVD.3,47 Finally, vitamin K, 
via the action of the Matrix Gla protein, is important 
in the inhibition of pathological arterial calcification,48,49 
a potent marker of increased cardiovascular disease 
risk.5 A randomized controlled trial of 388 older men 
and women observed a protective effect of vitamin 
K1 supplementation on the progression of coronary 
calcification, but only in a subset of patients with es-
tablished coronary calcification (coronary calcification 
score >10).10 Taken together, these data support the 
concept that diets rich in vitamin K may, in a multifac-
torial manner, reduce future ASCVD risk.
The current study has a number of implications for 
future research. First, the clinical importance of vitamin 
K deficiency has mostly been attributed to the accom-
panying coagulopathies. In light of the cardioprotective 
associations witnessed in the current study, further re-
search is needed to determine the thresholds of vita-
min K deficiency that may warrant intervention for the 
purpose of cardioprotection. Second, the differential 
effects of vitamin K on ASCVD subtypes warrants fur-
ther research to identify high- risk subgroups who may 
benefit from a diet high in vitamin K. Finally, further re-
search is needed into whether vitamin K supplemen-
tation is a safe and feasible primary prevention therapy 
for ASCVD.
Our study comes with some limitations common to 
nutritional epidemiology. First, the observational na-
ture of this study means that we cannot infer causal-
ity. Second, the ethnic homogeneity of the cohort may 
limit the overall generalizability of our findings. Third, the 
diet associated with higher vitamin K intake is generally 
healthy; however, we employed numerous methods 
to reduce the impact of residual dietary confounding, 
such as the use of a falsification end point, stratification 
of vitamin K1 intake by total vegetable intake, and ad-
justment for potential dietary confounders. Finally, the 
outcomes of interest were determined from ICD coding 
of hospital admissions, which are susceptible to error. 
However, our validated case analysis yielded compa-
rable results, indicating that any misclassification did 
not bias our results. The FFQ used in the current study 
was acquired from a single time point that represented 
a long preceding period, which may be susceptible 
to recall bias, and dietary behaviors may change over 
time. In addition, this FFQ has not been validated for vi-
tamin K, though prior studies have observed significant 
relationships between vitamin K determined from FFQs 
and serum markers of vitamin K intake.50 Importantly, 
the limitations of the FFQ would likely lead to a reduc-
tion in the power to detect an association, and the true 
relationship between vitamin K intake and ASCVD risk 
may be stronger than we report. Our study has sev-
eral significant strengths; a large sample size with up 
to 23 years of follow- up, allowing for the accumulation 
of a high number of events, the availability of important 
participant characteristics, enabling appropriate meth-
ods to be employed to reduce residual confounding 
and a very minimal loss to follow- up (<0.3%).
In this prospective cohort study, both dietary vi-
tamin K1 intake and vitamin K2 intake were inversely 
related to ASCVD hospitalization risk and very low vi-
tamin K1 was associated with a higher risk of ASCVD 
hospitalizations. Given the very different food sources, 
these data support an independent protective effect 
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needed to identify at- risk individuals who would ben-
efit most from increased dietary vitamin K intake or 
supplementation.
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Table S1. International Classification of Disease codes used to determine validated cases of 
atherosclerotic cardiovascular disease 
Validated Diagnosis ICD codes (ICD-8; ICD-10) Follow-up 
Myocardial infarction I21 10-02-1994 to 04-07-2013 
Peripheral artery disease I702, I702A, I739A, I739B, I739C 14-11-1994 to 07-12-2009 
Ischemic stroke I63 04-03-1994 to 30-11-2009 
The methods for validating these cases have been published previously35–39 . 
Table S2.  Anatomical Therapeutic Chemical codes for antihypertensive medications 
Use of antihypertensive 
medication was defined 
by the usage of any 
combination of at least 
two of the seven 
different drugs classes 
at the same time. 
Non-Loop: Thiazides C02L, C02DA, C07B, C07D, C09XA52, C03A, C03EA;  
Low-ceiling diuretics (excl. thiazides): C03B, C03X, C07C, C08G, C09BA, 
C09DA; potassium-sparing agents (spiron): C03D, C03E, C03EB 
Loop: high-ceiling diuretics (Loop) C03C, C03EB 
Antiadrenergic agents: C02A, C02B, C02C 
Beta-blockers: C07A, C07B, C07C, C07D, C07F 
Vasodilators: C02DB, C02DD, C02DG 
Calcium channel blockers: C08, C09BB, C09DB 
Renin angiotensin system inhibitors and angiotensin II receptor blockers: 













Table S3. Intakes and main dietary sources of vitamin K1 and vitamin K2 in the Danish Diet Cancer 
and Health cohort 
Vitamin K Median [IQR] intake (µg/day) Main dietary sources 
Vitamin K1 113.8 [80.7 – 151.2] Margarine (12.5%), lettuce (12.0%), broccoli 
(6.8%), wholemeal bread (6.9%), spinach (5.5%) 
Vitamin K2 43.7 [31.1 – 61.5]   
     MK-4 19.0 [13.4 – 25.4] Eggs (15%), butter (9.4%), cheese (6.8%) 
     MK-5 0.4 [0.3 – 0.5] Hard cheese (69.8%) 
     MK-6 0.6 [0.4 – 0.8] Hard cheese (33.7%) 
     MK-7 0.6 [ 0.4 – 0.9] Hard cheese (44.6%) 
     MK-8 5.3 [3.8 – 9.7] Hard cheese (59.1%), brie cheese (6.6%) 
     MK-9 13.2 [9.0 – 26.9] Hard cheese (71.2%), brie cheese (9.4%), blue 
cheese (6.2%) 
     MK-10 0.7 [ 0.4 – 1.7] Hard cheese (85.4%) 
Table S4. Association between incident atherosclerotic cardiovascular disease and vitamin K1 intake, stratified 
by tertiles of total vegetable intake 




Q1 Q2 Q3 Q4 Q5 
1        No. events 1 916 1 063 412 106 24 
         HR (95% CI) ref. 0.97 (0.90, 1.06) 0.93 (0.85, 1.02) 0.85 (0.74, 0.98) 0.74 (0.55, 0.99) 
2        No. events 201 693 922 687 216 
         HR (95% CI) ref. 0.84 (0.73, 0.96) 0.79 (0.67, 0.92) 0.76 (0.65, 0.88) 0.61 (0.50, 0.75) 
3        No. events 25 107 355 733 1 266 
         HR (95% CI) ref. 0.88 (0.79, 0.97) 0.78 (0.64, 0.95) 0.72 (0.55, 0.93) 0.73 (0.58, 0.93) 
Hazard ratios (95% CI) for atherosclerotic cardiovascular disease hospitalisations during 23 years of follow-up, 
obtained from Cox proportional hazards models using Model 1b for adjustment: age, sex, BMI, smoking status, 











Table S5. Hazard ratios of colorectal cancer hospitalisations by quintiles of vitamin K intake 
 Vitamin K intake quintiles 
 
 
Q1 Q2 Q3 Q4 Q5 
Vitamin K1     
Model 1b ref. 1.02 (0.92, 1.13) 1.02 (0.91, 1.14) 0.99 (0.88, 1.13) 0.93 (0.82, 1.07) 
Vitamin K2     
Model 1b ref. 1.02 (0.93, 1.12) 0.98 (0.88, 1.10) 0.91 (0.80, 1.02) 0.89 (0.78, 1.01) 
Hazard ratios (95% Confidence Intervals) for colorectal cancer hospitalisations (n = 1 716) during 23 years of follow-
up, obtained from restricted cubic splines based on Cox proportional hazards models. Model 1b adjusted for age, sex, 








Figure S1. Hazard ratios from Cox proportional hazards models using restricted cubic spline 
curves describing the association between vitamin K1 and vitamin K2 intake (µg/day) and 
validated cases of myocardial infarction (MI), peripheral artery disease (PAD), and ischemic 
stroke. 
 
Hazard ratios are based on Cox proportional hazards models adjusted for age, sex, BMI, smoking status, 
social economic status (income), physical activity, alcohol intake, and education (Model 1b), and are 
comparing the specific level of vitamin K intake (horizontal axis) to the median intake for participants 








Figure S2. The association between vitamin K1 intake (µg/day) and both total atherosclerotic 
cardiovascular disease (ASCVD) hospitalisations and subtypes of ASCVD hospitalisations 
(ischemic heart disease; peripheral artery disease; and ischemic stroke), after censoring 
participants upon prescription of a vitamin K antagonist.  
 
 
Hazard ratios are derived from Cox proportional hazards model with restricted cubic spline curves 
adjusting for age, sex, BMI, smoking status, social economic status (income), physical activity, alcohol 
intake, and education (Model 1b), and are comparing the specific level of vitamin K1 intake (horizontal 












Figure S3. The association between vitamin K2 intake (µg/day) and both total atherosclerotic 
cardiovascular disease (ASCVD) hospitalisations and subtypes of ASCVD hospitalisations 
(ischemic heart disease; peripheral artery disease; and ischemic stroke), after censoring 
participants upon prescription of a vitamin K antagonist. 
 
Hazard ratios are derived from Cox proportional hazards model with restricted cubic spline curves 
adjusting for age, sex, BMI, smoking status, social economic status (income), physical activity, alcohol 
intake, and education (Model 1b), and are comparing the specific level of vitamin K2 intake (horizontal 












Figure S4. Hazard ratios from Cox proportional hazards models using restricted cubic spline 
curves describing the association between vitamin K intake (µg/day) and both percutaneous 
coronary intervention (PCI) and coronary artery bypass grafting (CABG) procedures.  
 
 
Hazard ratios are based on Cox proportional hazards models adjusted for age, sex, BMI, smoking status, 
social economic status (income), physical activity, alcohol intake, and education (Model 1b), and are 
comparing the specific level of vitamin K intake (horizontal axis) to the median intake for participants 
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